open access

Vol 18, No 2 (2023)
Case report
Published online: 2022-05-30
Get Citation

Complications of percutaneous coronary intervention in 70 years old patient with multivessel coronary artery disease and prostate cancer

Kinga Zujko1, Narcyza Żygieło1, Małgorzata Knapp1, Anna Lisowska1
DOI: 10.5603/FC.a2022.0039
·
Folia Cardiologica 2023;18(2):84-86.
Affiliations
  1. Department of Cardiology, Medical University of Bialystok, Białystok, Poland

open access

Vol 18, No 2 (2023)
Case Reports
Published online: 2022-05-30

Abstract

A 70-year-old man with chronic coronary artery disease (CAD), disseminated atherosclerosis, heart failure with mildly reduced ejection fraction, hypertension, diabetes mellitus type 2 and prostate cancer was admitted to the Department of Cardiology because of low effort tolerance for further cardiological assessment before chemotherapy of prostate cancer. Due to the progression of CAD in coronarography, he was consulted at the Heart Team meeting and classified for two-step percutaneous coronary intervention (PCI). After PCI of the left anterior descending artery, he had a myocardial infarction with the ejection fraction decreased from 43% to 28%.

Abstract

A 70-year-old man with chronic coronary artery disease (CAD), disseminated atherosclerosis, heart failure with mildly reduced ejection fraction, hypertension, diabetes mellitus type 2 and prostate cancer was admitted to the Department of Cardiology because of low effort tolerance for further cardiological assessment before chemotherapy of prostate cancer. Due to the progression of CAD in coronarography, he was consulted at the Heart Team meeting and classified for two-step percutaneous coronary intervention (PCI). After PCI of the left anterior descending artery, he had a myocardial infarction with the ejection fraction decreased from 43% to 28%.

Get Citation

Keywords

percutaneous coronary intervention, multivessel coronary artery disease, artherosclerosis, heart failure, myocardial infarction, oncology, prostate cancer

About this article
Title

Complications of percutaneous coronary intervention in 70 years old patient with multivessel coronary artery disease and prostate cancer

Journal

Folia Cardiologica

Issue

Vol 18, No 2 (2023)

Article type

Case report

Pages

84-86

Published online

2022-05-30

Page views

642

Article views/downloads

140

DOI

10.5603/FC.a2022.0039

Bibliographic record

Folia Cardiologica 2023;18(2):84-86.

Keywords

percutaneous coronary intervention
multivessel coronary artery disease
artherosclerosis
heart failure
myocardial infarction
oncology
prostate cancer

Authors

Kinga Zujko
Narcyza Żygieło
Małgorzata Knapp
Anna Lisowska

References (8)
  1. Bryer E, Stein E, Goldberg S. Multivessel coronary artery disease. Mayo Clin Proc Innov Qual Outcomes. 2020; 4(6): 638–641.
  2. Nelson-Veniard M, Thambo JB. Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention. Bull Cancer. 2015; 102(7–8): 622–626.
  3. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2): 302–314, doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2.
  4. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989; 118(1): 92–98.
  5. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract. 2019; 47(1): 6–15.
  6. Opolski G, Krzakowski M, Szmit S, et al. Grupa Robocza Konsultantów Krajowych w Dziedzinie Kardiologii i Onkologii Klinicznej ds. opracowania rekomendacji postępowania kardiologicznego u chorych na raka piersi. Rekomendacje krajowego zespołu nadzoru kardiologicznego i onkologicznego dotyczące bezpieczeństwa kardiologicznego u chorych na raka piersi. Zapobieganie i postępowanie w powikłaniach sercowo-naczyniowych w raku piersi. Kardiol Pol. 2011; 69(5): 520–530.
  7. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007; 25(25): 3859–3865.
  8. Tripathy D, Seidman A, Keefe D, et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004; 5(4): 293–298.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media Group Sp. z o.o.Świętokrzyska 73, 80–180 Gdańsk

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl